Mirati Therapeutics Inc. | Key People and Executives
Charles M. Baum
President, Chief Executive Officer & Director
Rodney W. Lappe
Executive Chairman
Neil A. Reisman
Independent Director
Bruce Leonard Andrews Carter
Independent Director
Mike G. Grey
Independent Director
Craig A. Johnson
Independent Director
Henry J. Fuchs
Independent Director
Charles M. Baum
President, Chief Executive Officer & Director
Jamie A. Donadio
Chief Financial Officer & Senior Vice President
Claire S. Padgett
Senior Vice President-Clinical Operations
Isan Chen
EVP, Chief Medical & Development Officer
James G. Christensen
Chief Scientific Officer & Senior Vice President
Perry C. Johnston
Secretary, Chief Legal & Compliance Officer, VP
Christopher C. LeMasters
Chief Business Officer & Executive Vice President
Jessica M. Corson
Director-Business Development
Temre Johnson
Director-Investor Relations & Communications
Rodney W. Lappe
Executive Chairman
Neil A. Reisman
Independent Director
Bruce Leonard Andrews Carter
Independent Director
Michael G. Grey
Independent Director
Craig A. Johnson
Independent Director
Henry J. Fuchs
Independent Director
| Address |
9393 Towne Centre Drive
San Diego California 92121
United States
|
|
Employees
|
- |
| Website |
http://www.mirati.com |
| Updated |
07/08/2019 |
| Mirati Therapeutics, Inc. is a clinical-stage oncology company, which engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA. |
